Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.70 |
| ▸ | RXRB | P28702 | 1/20 | 0.70 |
| ▸ | RXRG | P48443 | 1/20 | 0.70 |
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.70 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783148 | 0.89 | FFAR4 (0.62) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL385027 | 0.89 | FFAR4 (0.62) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL7783922 | 0.88 | FFAR4 (0.60) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL69666 | 0.88 | RXRA (0.70) | RXRARXRBRXRGMRGPRX4NR4A2 | |
| SCHEMBL23226754 | 0.87 | FFAR4 (0.59) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL20059720 | 0.87 | LMNA (0.59) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL6812174 | 0.87 | SMN1; SMN2 (0.73) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL7319710 | 0.87 | FFAR4 (0.59) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL20898187 | 0.86 | MRGPRX4 (0.81) | RXRARXRBRXRGMRGPRX4FFAR4 | |
| SCHEMBL13440181 | 0.85 | FFAR4 (0.58) | RXRARXRBRXRGMRGPRX4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101117328-B | Fatty acid synthetase inhibitor and application for treating bacterial infection | INST PHARM & TOXICOLOGY AMMS | 2012-11-07 | — | — | CN | claimed |
| CN-101117328-A | Fatty acid synthetase inhibitor and application for treating bacterial infection | POISON MED INST PLA MED ACAD (CN) | 2008-02-06 | — | — | CN | claimed |
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | DUKE UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | UNIV DUKE (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | UNIV DUKE (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4058423-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | Duke University (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| WO-2021096968-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | DUKE UNIVERSITY (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2020-07-02 | — | — | US | disclosed |
| CN-110183431-A | One kind is for liver disease or the compound of prevention | 江苏新元素医药科技有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-101133037-A | Six-membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORP (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-101117328-A | Fatty acid synthetase inhibitor and application for treating bacterial infection | POISON MED INST PLA MED ACAD (CN) | 2008-02-06 | — | — | CN | disclosed |
| CN-1391562-A | Quinazoline derivatives as medicaments | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| CN-1062562-C | Corticosteroid 17-alkyl carbonate 21-[O]-carboxylic and carbonic esters, processes for their preparation, and pharmaceuticals containing these compounds | HOECHST AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| CN-1056151-C | 17-deoxycorticosteroid-21-[O]-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 2000-09-06 | — | — | CN | disclosed |
| CN-1051316-C | Corticoid 17,21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 2000-04-12 | — | — | CN | disclosed |
| CN-1124250-A | 17-deoxycorticosteroid-21-[O]-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1996-06-12 | — | — | CN | disclosed |
| CN-1108661-A | Corticoid 17,21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1995-09-20 | — | — | CN | disclosed |
| CN-1105368-A | Corticosteroid 17-alkyl carbonate 21-[O]-carboxylic and carbonic esters, processes for their preparation, and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1995-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | RXRA 1184/4885RXRB 1117/4885RXRG 1072/4885 |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | RXRA 1164/4885RXRB 1046/4885RXRG 1003/4885 |
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | CD47, SHBG, KLK3 | RXRA 126/4885RXRB 123/4885RXRG 35/4885 |
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | CD47, KLK3, SHBG | RXRA 203/4885RXRB 190/4885RXRG 150/4885 |
| US-20200207743-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | RXRA 1184/4885RXRB 1117/4885RXRG 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.